Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

10787	Companies
232914	Keywords
161476	Articles
124189	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 07/23/2025 at 14:30, 1 year ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 1 year ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 1 year ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 1 year ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 1 year 2 months ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 1 year 2 months ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 1 year 2 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRIEF

published on 04/09/2025 at 15:20, 1 year 3 months ago

Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRIEF

published on 04/09/2025 at 15:20, 1 year 3 months ago

Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC

Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
PRESS RELEASE

published on 04/09/2025 at 15:15, 1 year 3 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website

Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy

Accesswire

Published on 07/31/2026 at 01:39, 5 hours 46 minutes ago

Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 7 hours 40 minutes ago

Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 8 hours 24 minutes ago

Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 8 hours 25 minutes ago

Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:52, 12 hours 33 minutes ago

First Canadian Graphite annonce des résultats de prospection de graphite à haute teneur jusqu'à 43,4 % Cg au projet Lac Guéret Sud

View all ACCESSWIRE

EQS Group

Published on 07/31/2026 at 07:00, 24 minutes ago

Medacta Group SA: Medacta reports continued above-market revenue growth of 9.7% in c.c. in H1 2026
Published on 07/31/2026 at 07:00, 24 minutes ago

FUCHS reports strong first half of 2026
Published on 07/31/2026 at 06:30, 54 minutes ago

A successful first half of 2026 sets the stage for the second half
Published on 07/31/2026 at 06:30, 54 minutes ago

Executing the strategy and strengthening the market position
Published on 07/31/2026 at 06:30, 54 minutes ago

Strong first half with 11.5% organic growth in recurring EBIT, guidance upgraded

Les Echos

Published on 07/31/2026 at 07:00, 24 minutes ago

AXA - Half Year 2026 Earnings
Published on 07/31/2026 at 07:00, 24 minutes ago

AXA - Résultats semestriels 2026
Published on 07/30/2026 at 18:15, 13 hours 9 minutes ago

Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:15, 13 hours 9 minutes ago

Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 07/30/2026 at 18:05, 13 hours 19 minutes ago

Electricité de Strasbourg - Avis de mise à disposition de l'information financière du 1er semestre 2026

View all LES ECHOS COMFI WIRE